Payment overview · 2025
General Payments
$3,213.69
164 reported records · 27 companies
Healthcare provider profile · identity verified
Gerardo Bueso, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · HOUSTON, TX · NPI 1578658001
Verified facts
What the public records show
CMS Open Payments records show Gerardo Bueso, MD received $3,213.69 in general payments during 2025 across 164 reported records.
Corcept Therapeutics accounted for 10.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 888 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $344.11 | 10.7% | 17 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $309.74 | 9.6% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $280.97 | 8.7% | 16 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $272.14 | 8.5% | 14 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $233.89 | 7.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $213.30 | 6.6% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $207.50 | 6.5% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $185.77 | 5.8% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $165.11 | 5.1% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $128.51 | 4.0% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $102.55 | 3.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $98.40 | 3.1% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$94.30 | 2.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $77.14 | 2.4% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $70.46 | 2.2% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.75 | 2.1% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $62.62 | 1.9% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $53.12 | 1.6% | 4 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $52.25 | 1.6% | 3 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $45.62 | 1.4% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $35.75 | 1.1% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $24.51 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.97 | 0.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.68 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.59 | 0.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.47 | 0.5% | 1 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $13.47 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,213.69 | 164 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $344.11 | 17 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $309.74 | 12 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $272.14 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $265.05 | 15 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $233.89 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $207.50 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $204.07 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $165.11 | 12 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $165.07 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $160.43 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $110.21 | 7 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $102.55 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $98.40 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $94.30 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $77.14 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $70.46 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $68.75 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $62.62 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $53.12 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $53.12 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $53.12 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $52.25 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $45.62 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.38 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $35.75 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $11.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $7.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 170 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 139 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 888 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
136 | 39 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
34 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
139 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
164 | 45 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
888 | 231 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 888 | 231 |
| Metformin Hcl | Metformin Hcl | 848 | 286 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 206 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 446 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 150 |
| Losartan Potassium | Losartan Potassium | 357 | 115 |
| Lisinopril | Lisinopril | 240 | 73 |
| Farxiga | Dapagliflozin Propanediol | 233 | 71 |
| Glipizide | Glipizide | 187 | 61 |
| Omeprazole | Omeprazole | 177 | 59 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 176 | 90 |
| Jardiance | Empagliflozin | 170 | 64 |
| Trulicity | Dulaglutide | 164 | 45 |
| Tresiba Flextouch U-100 | Insulin Degludec | 159 | 52 |
| Alendronate Sodium | Alendronate Sodium | 152 | 46 |
| Gabapentin | Gabapentin | 144 | 49 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 143 | 39 |
| Mounjaro | Tirzepatide | 139 | 28 |
| Meloxicam | Meloxicam | 138 | 53 |
| Synthroid | Levothyroxine Sodium | 136 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 39 |
| Alprazolam | Alprazolam | 124 | 32 |
| Carvedilol | Carvedilol | 116 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 45 |
| Simvastatin | Simvastatin | 105 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 29 |
| Clonidine Hcl | Clonidine Hcl | 98 | 32 |
| Novolog Flexpen | Insulin Aspart | 96 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 32 |
| Humalog Kwikpen U-100 | Insulin Lispro | 83 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 27 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 36 |
| Tramadol Hcl | Tramadol Hcl | 80 | 13 |
| Glipizide Er | Glipizide | 79 | 28 |
| Azithromycin | Azithromycin | 74 | 63 |
| Humalog | Insulin Lispro | 74 | 17 |
| Montelukast Sodium | Montelukast Sodium | 74 | 27 |
| Tresiba Flextouch U-200 | Insulin Degludec | 74 | 26 |
| Januvia | Sitagliptin Phosphate | 72 | 17 |
| Furosemide | Furosemide | 71 | 28 |
| Allopurinol | Allopurinol | 70 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 24 |
| Ezetimibe | Ezetimibe | 68 | 28 |
| Methimazole | Methimazole | 68 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Atenolol | Atenolol | 56 | 17 |
| Hydrocortisone | Hydrocortisone | 56 | 13 |
| Nifedipine Er | Nifedipine | 56 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 20 |
| Glimepiride | Glimepiride | 55 | 18 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Spironolactone | Spironolactone | 46 | 17 |
| Eliquis | Apixaban | 45 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 16 |
| Sertraline Hcl | Sertraline Hcl | 45 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 13 |
| Enalapril Maleate | Enalapril Maleate | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 43 | 17 |
| Potassium Chloride | Potassium Chloride | 43 | 14 |
| Methylprednisolone | Methylprednisolone | 42 | 31 |
| Pregabalin | Pregabalin | 42 | 15 |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Nystatin | Nystatin | 40 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 15 |
| Ibuprofen | Ibuprofen | 39 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 38 | suppressed |
| Vascepa | Icosapent Ethyl | 38 | 12 |
| Famotidine | Famotidine | 36 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 11 |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 36 | suppressed |
| Prolia | Denosumab | 34 | 23 |
| Tradjenta | Linagliptin | 33 | 11 |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 30 | suppressed |
| Novolog | Insulin Aspart | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | 11 |
| Calcitriol | Calcitriol | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Lorazepam | Lorazepam | 27 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 13 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Levoxyl | Levothyroxine Sodium | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Omnitrope | Somatropin | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Cabergoline | Cabergoline | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Humatrope | Somatropin | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,213.69 · 164 records | Corcept Therapeutics | AFREZZA, CAPVAXIVE, CRENESSITY, CRYSVITA, CYCLOSET, CeQur Simplicity, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE, GARDASIL 9, GVOKE HYPOPEN, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NEXLETOL, Ozempic, QUTENZA, REPATHA, Rybelsus, SYNTHROID, TEPEZZA, TERIPARATIDE, TWIIST, TZIELD, Tymlos, Wegovy, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error